Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Jasper Therapeutics Inc.

Fitell Corporation ($FTEL), Jasper Therapeutics ($JSPR), and Boqii Holding ($BQ) are the 3&nbsp;Penny Stocks&nbsp;to watch on December 4. 2025, bas...

3 Penny Stocks to Watch Now, 12/4/25

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Jasper Therapeutics (JSPR – Research Report) and Azitra Inc (AZTR...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jasper Therapeutics (JSPR – Research Report) and A...

Market Cap	$49.81M	P/E Ratio	N/A
52W High	$23.11	52W Low	$1.39
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	43.4%	52W Position	1.7%
Overall Score	39	Value Score	60
Quality Score	31	Technical Score	27

EPS Current Est	$-4.94	EPS Next Est	$-2.75
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JSPR	$1.77	-3.80%	574.11K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JSPR	$1.77	-3.8%	574.11K
3
4
5
6

JSPR

JSPR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Jasper Therapeutics Inc. Data in Excel

Get Jasper Therapeutics Inc. Data in Excel